Company invests in DeSci blockchain innovation and purchases native coin of ResearchHub, a decentralized science platform co-founded by Coinbase CEO, Brian Armstrong
Silo Pharma, a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, announced its initial purchase of ResearchCoin (RSC) as part of its expanded digital assets treasury strategy designed to capture long-term value from emerging multi-chain opportunities. RSC is the native token of ResearchHub, a decentralized platform designed to advance scientific collaboration and discovery. ResearchHub was co-founded in 2019 by Coinbase CEO, Brian Armstrong.
“By securing a position in RSC, we are participating in the growing decentralized science (DeSci) movement while pursuing asset diversification and potential appreciation for shareholders,” said Eric Weisblum, CEO of Silo Pharma. “Our investment in ResearchCoin demonstrates our interest in modernizing scientific research and collaboration and supporting blockchain-driven innovation as a pillar for biomedical discovery.”
Read More on Fintech : Global Fintech Interview With Justin Meretab, Co‑Founder and CEO of Layer
Like DeFi, DeSci is a Web3 movement that emphasizes decentralization blockchain technologies and token-based economics. RSC tokens are designed to reward and encourage the sharing, review and curation of scientific knowledge. The ResearchHub platform enables a global community of researchers to collaborate, publish, and peer review in a transparent, tokenized environment—with a goal of accelerating discovery while ensuring contributors are recognized and rewarded for their work.
DeSci represents a transformative growth opportunity in the scientific research sector. The estimated trillion-dollar global research economy—currently tied up in grants, universities, and pharmaceutical pipelines—can potentially be unlocked and made liquid through tokenization. By tokenizing research funding and intellectual property, DeSci creates potential profit opportunities years before traditional biotech exits. Investors may be able to capture upside earlier, exit more flexibly, and access new avenues of growth in the biotech sector.
Catch more Fintech Insights : The CFO’s New Analyst: Using Generative AI for Strategic Financial Modeling
[To share your insights with us, please write to psen@itechseries.com ]
